KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Net Income towards Common Stockholders (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Net Income towards Common Stockholders readings, the most recent being $245.8 million for Q4 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 1017.5% to $245.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $263.9 million, a 396.87% increase, with the full-year FY2025 number at $263.9 million, up 396.87% from a year prior.
  • Net Income towards Common Stockholders hit $245.8 million in Q4 2025 for Biocryst Pharmaceuticals, up from $12.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $245.8 million in Q4 2025 to a low of -$75.3 million in Q2 2023.
  • Median Net Income towards Common Stockholders over the past 5 years was -$39.3 million (2022), compared with a mean of -$24.1 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: crashed 302.39% in 2022 and later skyrocketed 1017.5% in 2025.
  • Biocryst Pharmaceuticals' Net Income towards Common Stockholders stood at -$17.8 million in 2021, then plummeted by 302.39% to -$71.5 million in 2022, then grew by 13.71% to -$61.7 million in 2023, then skyrocketed by 56.59% to -$26.8 million in 2024, then skyrocketed by 1017.5% to $245.8 million in 2025.
  • The last three reported values for Net Income towards Common Stockholders were $245.8 million (Q4 2025), $12.9 million (Q3 2025), and $5.1 million (Q2 2025) per Business Quant data.